Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
about
The efficacy of bromfenac ophthalmic solution 0.07% dosed once daily in achieving zero-to-trace anterior chamber cell severity following cataract surgeryEtiology and treatment of the inflammatory causes of cystoid macular edema.The ocular distribution of (14)C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model.Ketorolac 0.45% ophthalmic solution.Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.One-Day Use of Preoperative Topical Nonsteroidal Anti-Inflammatory Drug Prevents Intraoperative Prostaglandin Level Elevation During Femtosecond Laser-Assisted Cataract Surgery.Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single siteEvaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy.Comparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.An update on the use of ophthalmic ketorolac tromethamine 0.4%.Comparison of Preoperative Topical Dexamethasone Phosphate Versus Ketorolac Tromethamine in Maintaining Intraoperative Mydriasis During Small Incision Cataract Surgery.Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs.Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence.Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions.Cataract surgery and its complications in diabetic patients.Cataract surgery and nonsteroidal antiinflammatory drugs.The effect of topical sodium diclofenac on macular thickness in diabetic eyes after phacoemulsification: a randomized controlled trial.Diabetic cataract-pathogenesis, epidemiology and treatment.Additive Effect of Oral Steroid with Topical Nonsteroidal Anti-inflammatory Drug for Preventing Cystoid Macular Edema after Cataract Surgery in Patients with Epiretinal Membrane.Ex vivo corneal epithelial wound healing following exposure to ophthalmic nonsteroidal anti-inflammatory drugs.Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.Intracameral ketorolac concentration at the beginning and end of cataract surgery following preoperative topical ketorolac administration.Electroacupuncture Attenuates Induction of Inflammatory Pain by Regulating Opioid and Adenosine Pathways in Mice.Impact of nepafenac 0.1% on macular thickness and postoperative visual acuity after cataract surgery in patients at low risk for cystoid macular oedema.The Effect of Latanaprost on Intraocular Inflammation and Macular Edema.
P2860
Q33680126-3780A673-26CF-4B1B-88E6-8DCBFACCBBC2Q34077613-0CD1AE99-4E73-436C-AF81-113E4D291B5EQ34160692-59C37E03-F18A-4593-8C5D-365B6AC9468FQ34196843-93A421FF-7359-49BE-A7AB-7BAFF7F6A118Q34806191-5DBA0941-7EC3-4D35-9B13-2DFFE190DA9BQ35872685-F12D0996-B4E5-4AAF-B921-8C806993456CQ36102155-8AC55698-9E26-432D-8703-74E4F2074DCFQ36173245-18163DC6-A41F-422E-BF4D-6DE8D0281EEBQ36295447-8544E2CA-1E47-487F-9882-8E368AEF8816Q36349621-F1ADFFC8-0558-413E-8E1C-7D9CCCB29DF3Q37102704-872F7A3C-8653-4771-988B-748B5D4B99D9Q37577432-550E7AD8-DB17-43AF-B20E-F9CF6B1454EEQ37577437-6D95B98E-181B-4FF3-A68A-5D4A384FC916Q37769529-102D1DD7-2A91-4FF1-8C3F-E1A04A4D5E5CQ38230010-85660DD6-EB6D-4DBF-BF7F-A04311D4DAF5Q38233855-2CD1DCA1-0AFC-4A75-9393-79A4CC191DD8Q38261111-28793C27-C90E-4445-88A9-0540E94DEBF1Q38970979-DA847B61-4E62-47D8-936D-446A55FF2728Q40854679-1042B7CC-D93D-4290-9CB7-56E222D5CC9CQ41776952-075F2698-2BE7-4CC2-B26D-6A6C15576938Q42262074-4AF4F425-6EF2-47E6-B52A-262A1571B750Q42704847-7A3996AA-CC8D-4379-B22E-F9ED701AA000Q43102831-395E2E23-CA4C-4DB4-A786-2635DE8E1E16Q44007858-AC310924-A7DB-44D7-84B3-CD0811AB67D3Q44350957-1B939D15-CB6A-418D-A360-A078008E1297Q46116440-CA7C5969-55BA-4BA2-9276-69DFE23853E6Q48189546-0443F28A-CA9A-4293-9582-B26164AAEEAC
P2860
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@ast
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@en
type
label
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@ast
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@en
prefLabel
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@ast
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@en
P356
P1476
Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.
@en
P2093
O'Brien TP
P304
P356
10.1185/030079905X50651
P407
P577
2005-07-01T00:00:00Z